IMMUNOVANT INC. - COMMON STOCK

Immunovant Appoints Mark Levine as Chief Legal Officer

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

07 Jan 2022 13:07:31 By Nasdaq GlobeNewswire

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

30 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

12 Nov 2021 11:18:05 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

05 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Immunovant to Participate in Roivant R&D Day 2021

27 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Immunovant Appoints Renee Barnett as Chief Financial Officer

15 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

09 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

06 Aug 2021 15:22:27 By Nasdaq GlobeNewswire

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

02 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

01 Jun 2021 06:31:18 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020

16 Feb 2021 07:00:04 By Nasdaq GlobeNewswire

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

02 Feb 2021 05:30:00 By Nasdaq GlobeNewswire

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

12 Jan 2021 16:00:00 By Nasdaq GlobeNewswire